Financiere de Tubize SA banner

Financiere de Tubize SA
XBRU:TUB

Watchlist Manager
Financiere de Tubize SA Logo
Financiere de Tubize SA
XBRU:TUB
Watchlist
Price: 204.2 EUR -2.95% Market Closed
Market Cap: €9.1B

Financiere de Tubize SA
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Financiere de Tubize SA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Financiere de Tubize SA
XBRU:TUB
Cash from Operating Activities
-€3.4m
CAGR 3-Years
-45%
CAGR 5-Years
-10%
CAGR 10-Years
7%
Ucb SA
XBRU:UCB
Cash from Operating Activities
€2.3B
CAGR 3-Years
27%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Hyloris Pharmaceuticals SA
XBRU:HYL
Cash from Operating Activities
-€7m
CAGR 3-Years
19%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
No Stocks Found

Financiere de Tubize SA
Glance View

Market Cap
9.1B EUR
Industry
Pharmaceuticals

Nestled in the heart of Belgium, Financiere de Tubize SA stands as a distinctive player in the world of investment holding companies, anchored in its robust shareholding strategy. Unlike many investment entities that diversify their portfolios across industries, Tubize has channeled its focus largely into the pharmaceutical sector through its significant shareholding in UCB, a global biopharmaceutical giant. This singular focus reflects a strategic commitment to capitalize on the growth and innovations within the healthcare industry, leveraging UCB's extensive research capabilities and expansive market presence. By holding a concentrated position in a company with established credentials in developing treatments for severe diseases, Tubize essentially acts as a conduit for investors to gain exposure to the burgeoning potential of biopharmaceutical advancements. The financial success of Financiere de Tubize SA is intricately tied to the performance of UCB. As UCB thrives and expands through its innovative drug developments and strategic market expansions, Tubize enjoys a consistent flow of dividends and capital appreciation. This dividend income underpins Tubize's operational model, allowing it to reinvest in its core holdings and distribute earnings to its own shareholders, thereby creating a cyclical flow of wealth generation and sustainability. Tubize's approach is akin to a watchful guardian, closely monitoring UCB's strategic paths while maintaining an investment structure that keeps administrative and operational costs minimal. Through such a streamlined focus, Financiere de Tubize SA offers investors a targeted and long-term pathway into the pharmaceutical sector, marked by careful oversight and strategic clarity.

TUB Intrinsic Value
22.07 EUR
Overvaluation 89%
Intrinsic Value
Price €204.2

See Also

What is Financiere de Tubize SA's Cash from Operating Activities?
Cash from Operating Activities
-3.4m EUR

Based on the financial report for Dec 31, 2025, Financiere de Tubize SA's Cash from Operating Activities amounts to -3.4m EUR.

What is Financiere de Tubize SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
7%

Over the last year, the Cash from Operating Activities growth was -63%. The average annual Cash from Operating Activities growth rates for Financiere de Tubize SA have been -45% over the past three years , -10% over the past five years , and 7% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett